Bevacizumab, a monoclonal antibody which targets vascular endothelial growth factor, can be applied to EGFR wild-type NSCLC, but does not improve overall survival for patients over the age of 65 [9]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.